Suppr超能文献

原发性纵隔大B细胞淋巴瘤:诊断难题

Primary Mediastinal Large B-cell Lymphoma: A Diagnostic Conundrum.

作者信息

Alrefai Yazan, Wadhwani Shruti, Wadhwani Nikita, Bangolo Ayrton, Mizrahi Jason, Feldman Tatyana

机构信息

Internal Medicine, University of Kentucky College of Medicine, Lexington, KY, USA.

Internal Medicine, Hackensack Meridian Health Palisades Medical Center, North Bergen, NJ, USA.

出版信息

Case Rep Oncol. 2025 May 14;18(1):711-719. doi: 10.1159/000545931. eCollection 2025 Jan-Dec.

Abstract

INTRODUCTION

Primary mediastinal large B-cell lymphoma (PMBCL) is a rare and aggressive non-Hodgkin lymphoma originating from mediastinal thymic B cells. Its peculiar molecular signature assists in differentiating it from other subtypes of non-Hodgkin lymphoma.

CASE REPORT

We present a rare case of PMBCL in a 39-year-old male with a bulky mediastinal mass that resulted in superior vena cava thrombosis and cardiac tamponade. Diagnostic discordance between histopathological and molecular data led to a delay in interception of this entity. Histopathology findings were suggestive of spindle-cell neoplasm. Contrastingly, next-generation sequencing (NGS) and immunohistochemistry (IHC) yielded a molecular diagnosis of PMBCL. IHC staining revealed that the atypical cells were positive for CD20, PAX5, CD79a, CD30, CD23, MUM1, and weakly positive for MAL (myelin and lymphocyte) protein. NGS showed increased expression of TNFRSF8 and CD274 genes, which encode CD30 and PDL1 proteins, respectively. The patient was successfully treated with the R-Hyper-CVAD protocol without consolidative radiotherapy.

CONCLUSION

Diagnosing PMBCL can be challenging because it lacks pathognomonic features and shares characteristics with other lymphomas. Molecular testing is of paramount importance in this context owing to its distinctive immunophenotype.

摘要

引言

原发性纵隔大B细胞淋巴瘤(PMBCL)是一种罕见的侵袭性非霍奇金淋巴瘤,起源于纵隔胸腺B细胞。其独特的分子特征有助于将其与非霍奇金淋巴瘤的其他亚型区分开来。

病例报告

我们报告一例罕见的39岁男性PMBCL病例,患者有巨大纵隔肿块,导致上腔静脉血栓形成和心脏压塞。组织病理学和分子数据之间的诊断不一致导致该疾病的诊断延误。组织病理学结果提示为梭形细胞瘤。相比之下,二代测序(NGS)和免疫组化(IHC)得出PMBCL的分子诊断。免疫组化染色显示非典型细胞CD20、PAX5、CD79a、CD30、CD23、MUM1呈阳性,MAL(髓磷脂和淋巴细胞)蛋白呈弱阳性。NGS显示TNFRSF8和CD274基因表达增加,这两个基因分别编码CD30和PDL1蛋白。该患者采用R-Hyper-CVAD方案成功治疗,未进行巩固性放疗。

结论

诊断PMBCL具有挑战性,因为它缺乏特征性表现且与其他淋巴瘤有共同特征。鉴于其独特的免疫表型,分子检测在这种情况下至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2632/12143869/71e339ed984f/cro-2025-0018-0001-545931_F01.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验